Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS)

Overview

Benign prostatic hyperplasia (BPH) is defined histologically. Several terms such as "prostatism", "symptoms of BPH", and "clinical BPH" have previously been used to describe male lower urinary tract symptoms (LUTS). These descriptions incorrectly imply that urinary symptoms in the male arise from the prostate. The acronym "LUTS" was introduced in order to avoid this. Increasingly, scientific communications on this syndrome use the term LUTS and avoid the use of the global term BPH. Nevertheless, BPH remains familiar to and commonly used by general practitioners, other clinicians, and patients when searching for clinical information and guidance. Clinically, the syndrome is characterised by lower urinary tract symptoms (urinary frequency, urgency, a weak and intermittent stream, needing to strain, a sense of incomplete emptying, and nocturia) and can lead to complications, including acute urinary retention.

Latest guidelines

Latest citations

Finasteride for benign prostatic hyperplasia. ( 09 September 2014 )

Combination Therapy with Solifenacin and Tamsulosin Oral Controlled Absorption System in a Single Tablet for Lower Urinary Tract Symptoms in Men: Efficacy and Safety Results from the Randomised Controlled NEPTUNE Trial. ( 09 September 2014 )

Latest guidelines

Latest citations

Finasteride for benign prostatic hyperplasia. ( 09 September 2014 )

Combination Therapy with Solifenacin and Tamsulosin Oral Controlled Absorption System in a Single Tablet for Lower Urinary Tract Symptoms in Men: Efficacy and Safety Results from the Randomised Controlled NEPTUNE Trial. ( 09 September 2014 )